Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 19, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 22, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
March 04, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at Upcoming Conferences
March 01, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
February 28, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024
February 22, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock
February 20, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 16, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024
February 16, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma
February 16, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
January 19, 2024
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer
December 27, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 22, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 17, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
November 07, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023
October 31, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
October 31, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 20, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Advanced Mucosal Melanoma at the European Society for Medical Oncology (ESMO) Congress
October 16, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 22, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
September 14, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
September 07, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
August 18, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
August 08, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
July 25, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
July 24, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 21, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
July 13, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
July 10, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
IOVA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.